Experimenting with a drug that stops cancer cells from repairing themselves and forces them to die Experimenting with a drug that stops cancer cells from repairing themselves and forces them to die

Experimenting with a drug that stops cancer cells from repairing themselves and forces them to die


Experimenting with a drug that stops cancer cells from repairing themselves and forces them to die


The new trial, funded by the breast cancer charity, sees researchers evaluating whether talazoparib can treat patients with late-stage breast cancer.

Scientists are studying the effectiveness of the drug talazoparib in helping to treat people with incurable breast cancer.

A report - published by the British newspaper "The Guardian " by health editor Andrew Gregory - stated that a new experiment could give hope to those suffering from incurable breast cancer, as research is being conducted to find out whether the drug talazoparib, also known as Talzenna, It will offer a new treatment for patients with incurable breast cancer that has reached the brain.

Secondary breast cancer, also known as metastatic breast cancer, is caused by the spread of cancer from the breast to other parts of the body.

The new trial, funded by the breast cancer charity, will see researchers assess whether talazoparib can treat patients with late-stage breast cancer. This drug is a PARP inhibitor (poly adenosine diphosphate-ribose polymerase) that works by preventing cancer cells from repairing themselves and forcing them to die.

Experts from the University of Medicine and Health Sciences Dublin will use tumors and breast cancer cells donated by patients to see if talazoparib is effective in treating secondary breast cancer in the brain, based on in vitro experiments. Further tests will examine the drug in mice, as well as models that mimic the brain's protective system.

Professor Leonie Young, one of the researchers involved in the study, said: “Our previous research has shown, in many cases, that secondary breast cancer tumors in the brain undergo changes in the way they repair DNA, and we believe that this may make them vulnerable to Barb inhibitor drugs. such as talazoparib.

Dr Simon Vincent, Director of Research, Support and Impact at Breast Cancer Now, said: "Around 35,000 people in the UK with incurable secondary breast cancer are overcome by fear and uncertainty about when this devastating disease will end their lives." "We urgently need to discover new ways to treat this incurable disease, including those whose breast cancer cells have reached the brain and who have very limited treatment options."

Post a Comment

Previous Post Next Post